

Erratum: Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020

A. Elkrief MD, P. Joubert MD, M. Florescu MD, M. Tehfe MD MSc, N. Blais MD MSc, and B. Routy MD PhD

Original Citation

Curr Oncol 2020;27:52–60. (doi: <https://doi.org/10.3747/co.27.5953>)

Description of the Error and Correction

In Table 1 in the initially published manuscript, several column headings are incorrectly presented.

- “IMpower150 (nonsquamous): atezolizumab plus bevacizumab plus platinum or paclitaxel” should read “IMpower150 (nonsquamous): atezolizumab plus bevacizumab plus platinum plus paclitaxel.”
- “KEYNOTE-189 (nonsquamous): pembrolizumab plus platinum or paclitaxel” should read “KEYNOTE-189 (nonsquamous): pembrolizumab plus platinum plus pemetrexed.”
- “IMpower130 (squamous): atezolizumab plus platinum or nab-paclitaxel” should read “IMpower130 (nonsquamous): atezolizumab plus platinum plus nab-paclitaxel.”
- “KEYNOTE-407 (squamous): pembrolizumab plus platinum or paclitaxel or nab-paclitaxel” should read “KEYNOTE-407 (squamous): pembrolizumab plus platinum plus paclitaxel or nab-paclitaxel.”

In Figure 2 in the initially published manuscript, in the BRAF box under “SECOND-LINE,” “Dabrafenib, trametinib” should be colour-coded orange, because that treatment regimen is Health Canada–approved.